Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats

Area of Science:

• Pharmacology
• Drug Delivery Systems
• Veterinary Medicine

Background:

• Subcutaneous drug delivery offers sustained release but requires safe and effective carrier systems.
• Buprenorphine is an opioid analgesic with potential for long-acting formulations.
• Assessing the safety of novel drug delivery vehicles is crucial before clinical application.

Purpose of the Study:

• To evaluate the target animal safety of a lipid suspension of buprenorphine administered subcutaneously.
• To determine the adverse events associated with increasing doses of buprenorphine in a lipid carrier.
• To assess the suitability of cholesterol-triglyceride carrier systems for long-acting subcutaneous buprenorphine therapy.

Main Methods:

• A Target Animal Safety protocol was employed using male and female Fischer F344/NTac rats.
• Rats received subcutaneous injections of buprenorphine in a lipid suspension at various doses.
• Comprehensive safety assessments included clinical observations, chemistry, hematology, coagulation, urinalysis, and histopathology.

Main Results:

• A single 0.65 mg/kg dose achieved clinically relevant buprenorphine blood levels for 3 days.
• Biochemical, hematological, and coagulation parameters remained within normal limits at 2- to 10-fold excess doses.
• No significant adverse histopathological findings were observed in surrounding tissues.
• Approximately 25% of rats at higher doses (1.3, 3.9, 6.5 mg/kg) exhibited transient nausea-related behaviors (grooming, self-gnawing).

Conclusions:

• Cholesterol-triglyceride carrier systems are confirmed as safe for subcutaneous buprenorphine delivery in laboratory animals.
• Lipid-based carriers demonstrate utility as effective scaffolds for long-acting subcutaneous drug therapy.
• The observed mild nausea-related behaviors at high doses warrant consideration but do not preclude the system's safety.